Kodiak Sciences Gets 'Buy' Rating: What Investors Need to Know
Kodiak gets a "Buy" rating and $15 target. Final results for its 3 eye drugs are due 2026. Watch for rival Roche's data soon.
NOTRELOAD AI
Wedbush Bullish on iPhone 17 and Apple AI Upside
Strong iPhone 17 demand and huge AI feature monetization are driving optimism. Wedbush target $310.
Anta's Arc’teryx Fireworks in Tibet Trigger Backlash And Probe
Arc’teryx caused outrage with a massive fireworks display in Tibet, which many said harmed the environment. This contradicted their nature-loving image. Authorities are investigating, and the brand apologized. Its parent company's stock dropped.
MBX Biosciences Advances Hypoparathyroidism Treatment to Phase 3
Once-weekly canvuparatide for hypoparathyroidism met its Phase 2 goal. 63% of patients achieved stable calcium and cut daily supplements. It was well tolerated and is advancing to Phase 3.
IREN Supercharges AI Cloud: Doubling Capacity and Targeting Half a Billion in Revenue!
IREN doubled its AI GPU fleet to 23,000 by investing $674M in top chips (NVIDIA/AMD). They now aim for over $500M in yearly revenue by early 2026 as global demand for fast compute power continues to surge, showing the strength of their platform.
Real Estate Giants Compass and Anywhere Merge in $10 Billion Deal
Compass is buying rival Anywhere Real Estate in an all-stock deal, creating a $10 billion real estate platform. This merger combines 340,000 professionals globally. Current Compass shareholders will own ~78%. Robert Reffkin leads the new company, expected to close in late 2026.